91°µÍø

A team of scientists led by the Department of Energy’s 91°µÍø designed a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and other viral diseases.

An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.

Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.  

Experiments led by researchers at ORNL have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce.

To better understand how the novel coronavirus behaves and how it can be stopped, scientists have completed a three-dimensional map that reveals the location of every atom in an enzyme molecule critical to SARS-CoV-2 reproduction.

A team of researchers has performed the first room-temperature X-ray measurements on the SARS-CoV-2 main protease — the enzyme that enables the virus to reproduce.

COVID-19 has upended nearly every aspect of our daily lives and forced us all to rethink how we can continue our work in a more physically isolated world.

Does vaping and smoking e-cigarettes put you at higher risk of COVID-19 complications? UWindsor’s Drew Marquardt is trying to answer that question with research into how the toxicants in the oils of vapes and e-cigarettes affect lung function.

In the race to identify solutions to the COVID-19 pandemic, researchers at the Department of Energy’s 91°µÍø are joining the fight by applying expertise in computational science, advanced manufacturing, data science and neutron science.